Company Analysis
Sign in

Akebia Therapeutics, Inc. (AKBA)

Nasdaq: AKBA · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2011
Full chart Alerts Compare
Grade5.3
◀ Past 4.2● Present 5.7▶ Future 6.0
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

33 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Akebia Therapeutics, Inc.’s names, not what it holds today.

Patents granted
33
32 utility, 1 reissue, 1976 to Dec 31, 2025
Granted in 2025
3
Against 2 in 2024 and 3 in 2023
Applications published
54
2 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals11
Organic fine chemistry2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Akebia Therapeutics, Inc. its own name
US, as the owner printed on each patent
33 granted
23 published
Akebia Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
31 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 25, 202512,478,615Prolyl hydroxylase inhibitors and methods of usePharmaceuticalsAkebia Therapeutics, Inc.
Sep 23, 202512,419,877Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereofPharmaceuticalsAkebia Therapeutics, Inc.
Apr 8, 202512,269,802Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino] acetic acidOrganic fine chemistryAkebia Therapeutics, Inc.
Jan 30, 202411,883,386Prolyl hydroxylase inhibitors and methods of usePharmaceuticalsAkebia Therapeutics, Inc.
Jan 2, 202411,857,543Compositions and methods for treating anemiaPharmaceuticalsAkebia Therapeutics, Inc.
Dec 19, 202311,844,756Compositions and methods for treating anemiaPharmaceuticalsAkebia Therapeutics, Inc.
Aug 1, 202311,713,298Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acidOrganic fine chemistryAkebia Therapeutics, Inc.
Jul 4, 202311,690,836Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereofPharmaceuticalsAkebia Therapeutics, Inc.
Dec 13, 202211,524,939Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acidPharmaceuticalsAkebia Therapeutics, Inc.
Aug 30, 202211,426,393Prolyl hydroxylase inhibitors and methods of usePharmaceuticalsAkebia Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 20, 20252025/0352527METHODS FOR TREATING VIRAL INFECTIONS, ORGAN INJURY, AND RELATED CONDITIONSPharmaceuticalsAkebia Therapeutics, Inc.
Jul 31, 20252025/0243164PROCESS FOR PREPARING 2-[[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO]ACETIC ACIDOrganic fine chemistryAkebia Therapeutics, Inc.
Oct 31, 20242024/0358691PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USEPharmaceuticalsAkebia Therapeutics, Inc. · patent 12,478,615 granted from it
Oct 10, 20242024/0336568SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USEPharmaceuticalsAkebia Therapeutics, Inc.
Oct 10, 20242024/0335434COMPOSITIONS AND METHODS FOR TREATING ANEMIAPharmaceuticalsAkebia Therapeutics, Inc.
Oct 3, 20242024/0327376PICOLINAMIDE COMPOUNDS AS SELECTIVE PHD1 INHIBITORS, COMPOSITIONS, AND METHODS OF USEPharmaceuticalsAkebia Therapeutics, Inc.
Oct 3, 20242024/0325361Compositions and Methods for Treating AnemiaPharmaceuticalsAkebia Therapeutics, Inc.
Oct 3, 20242024/0325360THERAPEUTIC METHODS USING VADADUSTATPharmaceuticalsAkebia Therapeutics, Inc.
May 16, 20242024/0158354Process for Preparing 2-[[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino]Acetic AcidOrganic fine chemistryAkebia Therapeutics, Inc. · patent 12,269,802 granted from it
May 9, 20242024/0148707MODULATION OF DRUG-DRUG INTERACTIONS OF VADADUSTATPharmaceuticalsAkebia Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 9 · Organic fine chemistry 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton AKBA · research, not advice